T17-036

Tohoku University's Invention

Lymphatic drug delivery system



Administration of little amount of prepared liquid drug shows excellent antitumor efficacy!

Introduction

Many cancers spread to regional lymph nodes lymphatic vessels. through the Intravenous administration of chemotherapeutic agents through blood vessels is a common treatment for metastatic lymph nodes. Drugs administered intravenously leak from the capillaries into the interstitium in peripheral tissues and are reabsorbed by the blood vessels and lymphatic vessels. However, the lymphatic system is characterized by the preferential uptake of large-sized particles and polymers, and thus anticancer drugs, which are generally small molecules, are considered difficult to deliver to the lymphatic system.

A modern drug delivery system by lymphatic vessels can deliver drugs to a target lymph nodes directly. In this way, not only these lymph nodes, but also the downstream lymphatic system can be treated properly.

This invention shows that a liquid preparation having a particular osmotic pressure range provided high drug retention in the target lymph node, high delivery to the downstream lymph node, and excellent drug efficacy.

The investigation for diseases other than cancers is being researched with data unpublished.

Injection of tumor cells to proper axillary lymph node (PALN)

Injection of anticancer drug

<Pathological images at PLAN>

Drug not delivered



Anticancer effect by lymphatic drug delivery system



This invention N 1_mm

On the 3rd day after injection of the tumor cells to PLAN (Day 0), 200µL anticancer drug was administrated to SiLN.

On the 9th day, a pathological evaluation was made for PLAN.

<This model mouse>
Having comparable size of lymph
nodes as human being.



Tumor cells grew in the marginal sinus of the lymph node and the parenchymal equivalent of the lymph node.

Tumor cells grew in the marginal sinus of the lymph node and the parenchymal equivalent of the lymph node, and <u>extensive necrotic foci</u> were recognized. No tumor cells remained due to the marked antitumor effect.

Contact

Tohoku Techno Arch Co., LTD TEL:+81-22-222-3049, FAX:+81-22-222-3419 <u>Click</u> to contact

Patent Data Sheet

Publication No.(Serial No.): WO2019/45005 (T17-036) Inventor: KODAMA Tetsuya, MORI shiro